A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Medicine and Dentistry

• Systematic Review 100%
• Health Care Cost 100%
• Immune Checkpoint Inhibitor 100%
• Cost-Effectiveness Analysis 100%
• Nivolumab 100%
• Effectiveness Study 100%
• Pembrolizumab 63%
• Ipilimumab 36%
• Non Small Cell Lung Cancer 27%
• Melanoma 27%
• Monotherapy 27%
• Head and Neck Cancer 18%
• Urogenital Tract Cancer 18%
• Programmed Death-Ligand 1 18%
• Cancer 9%
• Clinical Trial 9%
• Oncology 9%
• Lung 9%
• Neck 9%
• Bladder Cancer 9%
• Patient Selection 9%
• Quality Adjusted Life Year 9%

Keyphrases

• Immune Checkpoint Inhibitors 100%
• Nivolumab 100%
• Cost-effectiveness Study 100%
• Cost-effectiveness 63%
• Pembrolizumab 63%
• Ipilimumab 36%
• Melanoma 27%
• Monotherapy 27%
• Non-small Cell Lung Cancer (NSCLC) 18%
• Head-and-neck Cancer 18%
• Genitourinary Cancer 18%
• Programmed Death-ligand 1 (PD-L1) 18%
• Clinical Trials 9%
• Oncology 9%
• Lung 9%
• Chemotherapy 9%
• Malignancy 9%
• Patient Selection 9%
• Renal Cancer 9%
• Bladder Cancer 9%
• Health Care Costs 9%
• Head-and-neck 9%
• Newly Diagnosed 9%
• Long Follow-up 9%
• Previously Treated 9%
• Existing Data 9%
• Metastatic Non-small Cell Lung Cancer 9%
• PubMed Database 9%
• Economic Impact 9%
• Recurrent Metastatic 9%
• Expensive Therapies 9%
• Value-based 9%
• Willingness to Pay 9%
• Unresected 9%
• Willingness-to-pay Threshold 9%
• PRISMA 9%